iSpecimen Net Income
| ISPC Stock | USD 0.32 0.01 3.03% |
As of the 11th of February 2026, ISpecimen retains the Standard Deviation of 7.62, risk adjusted performance of (0.08), and Market Risk Adjusted Performance of (0.35). ISpecimen technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
ISpecimen Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.2116 | Revenue | Earnings Share (7.82) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -11.2 M | -11.8 M | |
| Net Loss | -9.2 M | -9.7 M | |
| Net Loss | -11.2 M | -11.8 M | |
| Net Loss | (15.82) | (16.61) | |
| Net Income Per E B T | 1.11 | 1.07 |
ISpecimen | Net Income | Build AI portfolio with ISpecimen Stock |
Analyzing ISpecimen's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ISpecimen's current valuation and future prospects.
Latest ISpecimen's Net Income Growth Pattern
Below is the plot of the Net Income of iSpecimen over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in iSpecimen financial statement analysis. It represents the amount of money remaining after all of iSpecimen operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ISpecimen's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ISpecimen's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (12.5 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ISpecimen Net Income Regression Statistics
| Arithmetic Mean | (7,256,828) | |
| Coefficient Of Variation | (40.29) | |
| Mean Deviation | 2,626,178 | |
| Median | (5,347,052) | |
| Standard Deviation | 2,923,505 | |
| Sample Variance | 8.5T | |
| Range | 7.8M | |
| R-Value | (0.82) | |
| Mean Square Error | 3T | |
| R-Squared | 0.67 | |
| Significance | 0.000061 | |
| Slope | (473,310) | |
| Total Sum of Squares | 136.8T |
ISpecimen Net Income History
Other Fundumenentals of iSpecimen
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ISpecimen Net Income component correlations
ISpecimen Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ISpecimen is extremely important. It helps to project a fair market value of ISpecimen Stock properly, considering its historical fundamentals such as Net Income. Since ISpecimen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ISpecimen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ISpecimen's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could ISpecimen diversify its offerings? Factors like these will boost the valuation of ISpecimen. Market participants price ISpecimen higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ISpecimen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.82) | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, ISpecimen's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
ISpecimen 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ISpecimen's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ISpecimen.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in ISpecimen on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding iSpecimen or generate 0.0% return on investment in ISpecimen over 90 days. ISpecimen is related to or competes with ENDRA Life, Theriva Biologics, Catheter Precision, Heart Test, Galmed Pharmaceuticals, Bluejay Diagnostics, and Biovie. iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living ... More
ISpecimen Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ISpecimen's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess iSpecimen upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 37.8 | |||
| Value At Risk | (11.76) | |||
| Potential Upside | 11.54 |
ISpecimen Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ISpecimen's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ISpecimen's standard deviation. In reality, there are many statistical measures that can use ISpecimen historical prices to predict the future ISpecimen's volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.04) | |||
| Total Risk Alpha | (1.63) | |||
| Treynor Ratio | (0.36) |
ISpecimen February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.35) | |||
| Mean Deviation | 5.47 | |||
| Coefficient Of Variation | (911.39) | |||
| Standard Deviation | 7.62 | |||
| Variance | 58.03 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (1.04) | |||
| Total Risk Alpha | (1.63) | |||
| Treynor Ratio | (0.36) | |||
| Maximum Drawdown | 37.8 | |||
| Value At Risk | (11.76) | |||
| Potential Upside | 11.54 | |||
| Skewness | 0.9918 | |||
| Kurtosis | 2.7 |
iSpecimen Backtested Returns
iSpecimen holds Efficiency (Sharpe) Ratio of -0.0994, which attests that the entity had a -0.0994 % return per unit of risk over the last 3 months. iSpecimen exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out ISpecimen's Market Risk Adjusted Performance of (0.35), risk adjusted performance of (0.08), and Standard Deviation of 7.62 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.34, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ISpecimen will likely underperform. At this point, iSpecimen has a negative expected return of -0.79%. Please make sure to check out ISpecimen's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if iSpecimen performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.3 |
Weak reverse predictability
iSpecimen has weak reverse predictability. Overlapping area represents the amount of predictability between ISpecimen time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of iSpecimen price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current ISpecimen price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ISpecimen Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, iSpecimen reported net income of (12.5 Million). This is 103.66% lower than that of the Biotechnology sector and 107.22% lower than that of the Health Care industry. The net income for all United States stocks is 102.19% higher than that of the company.
ISpecimen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ISpecimen's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ISpecimen could also be used in its relative valuation, which is a method of valuing ISpecimen by comparing valuation metrics of similar companies.ISpecimen is currently under evaluation in net income category among its peers.
ISpecimen Institutional Holders
Institutional Holdings refers to the ownership stake in ISpecimen that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ISpecimen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ISpecimen's value.| Shares | Citadel Advisors Llc | 2025-06-30 | 19.5 K | Geode Capital Management, Llc | 2025-06-30 | 14.8 K | Ubs Group Ag | 2025-06-30 | 14 K | Xtx Topco Ltd | 2025-06-30 | 10.1 K | Tower Research Capital Llc | 6.2 K | Blackrock Inc | 2.8 K | Bank Of America Corp | 22.0 | Sbi Securities Co Ltd | 7.0 | Sachetta Llc | 1996-06-30 | 2.0 | Bridgeway Capital Management, Llc | 2025-06-30 | 0.0 |
ISpecimen Fundamentals
| Return On Equity | -2.96 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (26.55) % | ||||
| Current Valuation | 709.43 K | ||||
| Shares Outstanding | 9.77 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 3.57 % | ||||
| Number Of Shares Shorted | 311.31 K | ||||
| Price To Earning | 0.78 X | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 0.96 X | ||||
| Revenue | 9.29 M | ||||
| Gross Profit | 722.54 K | ||||
| EBITDA | (12.73 M) | ||||
| Net Income | (12.5 M) | ||||
| Cash And Equivalents | 23.69 M | ||||
| Cash Per Share | 2.67 X | ||||
| Total Debt | 312.17 K | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 13.37 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (8.26 M) | ||||
| Short Ratio | 0.13 X | ||||
| Earnings Per Share | (7.82) X | ||||
| Price To Earnings To Growth | (0.09) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 24 | ||||
| Beta | 1.84 | ||||
| Market Capitalization | 3.21 M | ||||
| Total Asset | 9.35 M | ||||
| Retained Earnings | (71.86 M) | ||||
| Working Capital | (2.18 M) | ||||
| Net Asset | 9.35 M |
About ISpecimen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iSpecimen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ISpecimen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iSpecimen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:Check out For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Will Biotechnology sector continue expanding? Could ISpecimen diversify its offerings? Factors like these will boost the valuation of ISpecimen. Market participants price ISpecimen higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ISpecimen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.82) | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, ISpecimen's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.